Corrigendum: Blood neurofilament light chain as a biomarker for monitoring and predicting paclitaxel-induced peripheral neuropathy in patients with gynecological cancers

Front Oncol. 2023 Sep 7:13:1279558. doi: 10.3389/fonc.2023.1279558. eCollection 2023.

Su-Hyun Kim¹, Ki Hoon Kim¹, Jae-Won Hyun¹, Ji Hyun Kim², Sang-Soo Seo², Ho Jin Kim¹, Sang-Yoon Park², Myong Cheol Lim^{2

3

4

5

6}

¹ Department of Neurology, Research Institute and Hospital of National Cancer Center, Goyang, Republic of Korea.
² Center for Gynecologic Cancer, National Cancer Center, Goyang, Republic of Korea.
³ Center for Clinical Trial, Hospital, National Cancer Center, Goyang, Republic of Korea.
⁴ Department of Cancer Control and Population Health, National Cancer Center Graduate School of Cancer Science and Policy, Goyang, Republic of Korea.
⁵ Rare and Pediatric Cancer Branch and Immuno-oncology Branch, Division of Rare and Refractory Cancer, Research Institute, National Cancer Center, Goyang, Republic of Korea.
⁶ Department of Cancer Control and Policy, National Cancer Center, Goyang, Republic of Korea.

Abstract

[This corrects the article DOI: 10.3389/fonc.2022.942960.].

Keywords: chemotherapy induced peripheral neuropathy; gynecological cancer; neurofilament light (NfL); neuropathy; paclitaxel.